BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Bruton’s tyrosine kinase inhibitor (BTKi) BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
https://finance.yahoo.com/news/brukinsa-approved-u-chronic-lymphocytic-220300917.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.